Related Experiment Video
Updated: Sep 12, 2026

Development and Maintenance of a Preclinical Patient Derived Tumor Xenograft Model for the Investigation of Novel Anti-Cancer Therapies
Published on: September 30, 2016
Update on European adjuvant trials with irinotecan for colorectal cancer
Jean-Yves Douillard1, Veronique Barbarot, Jaafar Bennouna
1Centre Rene Gauducheau, CRLCC Nantes-Atlantique, St Herblain-Nantes, France. jy-douillard@nantes.fnclcc.fr
Abstract:
Recent combinations of chemotherapy have significantly improved the response rate and survival time for patients with metastatic colorectal cancer. This improvement has been initially demonstrated with the combination of fluorouracil (5-FU)/leucovorin and irinotecan (CPT-11, Camptosar), which now is considered and recommended as first-line treatment. The combination of improved efficacy with survival benefit should translate into a better cure rate in patients with resected, locally advanced, nonmetastatic colorectal cancer for whom adjuvant chemotherapy with 5-FU/leucovorin is of proven benefit. Several randomized phase III trials are ongoing in Europe or would begin shortly to assess the potential benefit of a 5-FU/leucovorin-irinotecan combination in the adjuvant setting for patients with stage II or III colorectal cancer. This article will review the inclusion criteria and goal of these European trials. An update on accrual and on tolerance will also be provided.
Related Concept Videos
Clinical Trials
There are four phases in a clinical trial. A phase one...
Clinical Trials: Overview
Drugs for Treatment of Diarrhea-Predominant IBS
Two specific drugs used in the treatment are alosetron (Lotronex) and eluxadoline (Viberzi). Alosetron, a 5-HT3 antagonist, works by slowing the movement of stools in the gut, reducing bowel...
Drugs for Treatment of Constipation-Predominant IBS
Drugs for Treatment of Ulcerative Colitis in IBD
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents

